Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $34.0 million.

  • Taysha Gene Therapies' Operating Expenses rose 2289.24% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 1100.65%. This contributed to the annual value of $99.8 million for FY2024, which is 1354.19% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Operating Expenses is $34.0 million, which was up 2289.24% from $28.7 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Operating Expenses peaked at $56.5 million during Q4 2022, and registered a low of $19.8 million during Q4 2023.
  • Moreover, its 4-year median value for Operating Expenses was $25.8 million (2023), whereas its average is $29.3 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Operating Expenses tumbled by 6484.73% in 2023, and later soared by 3186.32% in 2024.
  • Taysha Gene Therapies' Operating Expenses (Quarter) stood at $56.5 million in 2022, then plummeted by 64.85% to $19.8 million in 2023, then grew by 10.6% to $22.0 million in 2024, then surged by 54.98% to $34.0 million in 2025.
  • Its last three reported values are $34.0 million in Q3 2025, $28.7 million for Q2 2025, and $23.7 million during Q1 2025.